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N-glycosylation of mouse TRAIL-R and human
TRAIL-R1 enhances TRAIL-induced death
Florent Dufour1,11, Thibault Rattier1,11, Sarah Shirley1,11, Gaelle Picarda2, Andrei Alexandru Constantinescu1, Aymeric Morlé1,
Al Batoul Zakaria3, Guillaume Marcion1, Sebastien Causse1, Eva Szegezdi4, Dirk Michael Zajonc2,5, Renaud Seigneuric1,
Gilles Guichard6, Tijani Gharbi3, Fabien Picaud3, Guillaume Herlem3, Carmen Garrido1,7,8,9, Pascal Schneider10, Chris Alan Benedict2
and Olivier Micheau*,1,7,8
APO2L/TRAIL (TNF-related apoptosis-inducing ligand) induces death of tumor cells through two agonist receptors, TRAIL-R1 and
TRAIL-R2. We demonstrate here that N-linked glycosylation (N-glyc) plays also an important regulatory role for TRAIL-R1-mediated
and mouse TRAIL receptor (mTRAIL-R)-mediated apoptosis, but not for TRAIL-R2, which is devoid of N-glycans. Cells expressing
N-glyc-defective mutants of TRAIL-R1 and mouse TRAIL-R were less sensitive to TRAIL than their wild-type counterparts.
Defective apoptotic signaling by N-glyc-deficient TRAIL receptors was associated with lower TRAIL receptor aggregation and
reduced DISC formation, but not with reduced TRAIL-binding affinity. Our results also indicate that TRAIL receptor N-glyc impacts
immune evasion strategies. The cytomegalovirus (CMV) UL141 protein, which restricts cell-surface expression of human TRAIL
death receptors, binds with significant higher affinity TRAIL-R1 lacking N-glyc, suggesting that this sugar modification may have
evolved as a counterstrategy to prevent receptor inhibition by UL141. Altogether our findings demonstrate that N-glyc of TRAIL-R1
promotes TRAIL signaling and restricts virus-mediated inhibition.
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APO2L/TRAIL (TNF-related apoptosis-inducing ligand)
belongs to the TNF subfamily of apoptosis-inducing ligands.1
This promising anti-tumor compound has attracted much
interest in oncology due to its ability to trigger selective cell
death in a large variety of human tumors.2 Owing to its
restricted expression on immune cells, TRAIL plays an
important physiological function during both tumor and viral
immune surveillance.3 TRAIL triggers apoptosis by binding to
one or both of its agonist receptors, namely TRAIL-R1/DR4
and/or TRAIL-R2/DR5.4 TRAIL binding induces the formation
of a membrane-bound death-inducing signaling complex
(DISC), formed by the recruitment of caspase-8 and
caspase-10 to TRAIL-R1 and/or TRAIL-R2 via the adaptor
protein FADD.5 Recruitment of initiator caspases to the DISC
allows their activation and subsequent release in the cytosol
where they cleave and activate effector caspases, including
caspase-3, leading to cell dismantling.6 Conversely, binding of
TRAIL to its regulatory receptors TRAIL-R3/DcR1 or TRAIL-
R4/DcR2 selectively impairs the engagement of the apoptotic
machinery.7,8 Besides regulation provided by differential
expression of agonist or antagonist receptors, cell sensitivity
to TRAIL can also be controlled by their post-translational
modifications. For example, O-glycosylation of the cysteine-
rich domains of TRAIL-R2 is required for efficient TRAIL DISC
formation and apoptosis.9 However, whether glycosylation-
mediated regulation is a conserved feature of the death
receptor family remains, so far, unclear.
Cytomegalovirus (CMV/HHV-5, the prototypic β-herpes-
virus) establishes lifelong persistence/latency despite a robust
host immune response, as do all herpes viruses. CMV
infection is essentially benign in healthy, young persons, but
causes severe diseases if immunity is compromised or naïve
(e.g. transplants, AIDS, congenital infection).10,11 Both human
and mouse CMV dedicate more than half of their ~ 230 kB
DNA genomes to open reading frames that modulate host
immune defenses,12,13 many of which target signaling by TNF
family cytokines.14 Our previous work revealed that the HCMV
UL141 protein promotes intracellular retention of both TRAIL-
R1 and TRAIL-R2,15 a function similarly performed by the
MCMV m166 protein to mTRAIL-R,16 contributing to the
resistance of CMV-infected cells to killing by TRAIL-
expressing NK cells. UL141 is an immunoglobulin (Ig) fold-
containing protein that is structurally unrelated to TRAIL.
Analysis of the crystal structure of UL141 in complex with
TRAIL-R2 revealed that UL141 binds uniquely to TRAIL-R2,
only partially overlapping with the TRAIL-binding site.17
In the present study, we show that N-glycosylation (N-glyc)
increases TRAIL-induced receptor aggregation and apoptosis
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by both human TRAIL-R1 and mTRAIL-R. We also provide
evidence that CMV UL141 binds with higher affinity to TRAIL-
R1 lacking N-glyc, suggesting N-glyc of this death receptor,
which is absent in TRAIL-R2, may have evolved in response to
virus-imposed pressure.
Results
Cell death induced by human TRAIL-R1 is regulated by
N-glycosylation. Despite clear evidence demonstrating that
O-glycosylation (O-glyc) is required for efficient TRAIL-R2-
induced apoptosis in human tumor cells,9 it remains unclear
whether this post-translational modification might similarly
regulate apoptosis induced by TRAIL-R1 or by the single rodent
agonist receptor ortholog, mTRAIL-R (also coined as mouse
killer or MK).18 Specifically, TRAIL-induced cell death was
impaired when eight serine and threonine residues of TRAIL-R2
(SSS74,75,77AAA and TTTTT130,131,132,135,143AAAAA)
were mutated9 of which S77, T130 and T135 are predicted to
be putative O-glyc sites using the bioinformatic tool GlycoEP.19
TheseO-glyc sites, albeit well conserved in most primate TRAIL-
R2 orthologs, are poorly conserved in rodents (Figure 1a and
Supplementary Figure S1). Additionally, predicted O-glyc sites in
primates are also less conserved in TRAIL-R1 than in TRAIL-
R2, with the exception of the threonine stretch at the end of the
first cysteine-rich repeat (CRD1) (Figure 1a and Supplementary
Figure S1). Interestingly, however, while TRAIL-R2 is devoid of
N-glyc sites, one conserved consensus site is present within the
first cysteine-rich domains of TRAIL-R1 in six out of seven
primate species (Supplementary Figure S1). Conserved putative
N-glyc sites are also present in mTRAIL-R (Figure 1a and
Supplementary Figure S1), either at the beginning of CRD1 in
the '50s loop', which interacts with TRAIL,20 or at the end of
CRD1 (Supplementary Figures S1 and S2).
Since N-glyc plays a regulatory role for other members of
the TNF family, including CD95/Fas,21 we investigated the
N-glyc status of TRAIL-R1 in a panel of human colorectal
cancer and B-cell lymphoma cell lines. The human colon
cancer cell lines SW480 and HCT116 express both TRAIL-R1
and TRAIL-R2 (Figure 1b) and are sensitive to TRAIL-induced
cell death (Figure 1c). Apoptosis in these cells could be
induced either through TRAIL-R1 using the TRAIL mutant
ligand 4C922 or through TRAIL-R2 using the TRAIL peptido-
mimetic M1d23 (Figure 1c). In contrast, several B-lymphomas
cells lines (VAL, BL2, RL, SUDHL4, Ramos) engaged
apoptosis preferentially through TRAIL-R1 (Figure 1d), irre-
spective of their relative expression of the TRAIL receptors
(Supplementary Figure S3a and ref. 24) or their sensitivity to
Fas ligand (Figure 1d). In all of these tumor cell lines TRAIL-R1
was N-glycosylated, as demonstrated by removal of N-linked
glycanswith peptideN-glycanase F (PNGaseF), which shifted
TRAIL-R1 migration to the expected theoretical molecular
weight (MW) of 42 kDa (Figures 1e and f). Consistent with the
absence of predicted N-glyc sites, TRAIL-R2 expressed in
colon cancer cell lines was unaffected by PNGaseF
(Figure 1e). In order to determine the impact of N-glycosyla-
tion on the apoptotic activity of TRAIL-R1, U2OS cells
expressing low levels of TRAIL-R2 and nearly undetectable
levels of TRAIL-R1 (Figure 2a) were reconstituted with
equivalent levels of wild type (TRAIL-R1WT) or an N-glyc-
osylation-deficient mutant of TRAIL-R1 (TRAIL-R1N156A)
(Figure 2a). TRAIL-R1N156A migrated with a lower apparent
MW than TRAIL-R1WT in U2OS cells, was insensitive to
PNGaseF digestion and migrated identically to TRAIL-R1WT
from cell extracts treated with PNGaseF, indicating that TRAIL-
R1 contains a single N-linked glycan on N156 (Figure 2b).
Contrary to parental U2OS cells, which are poorly sensitive to
TRAIL- and Fas ligand-induced cell death (Supplementary
Figure S3b), U2OS cells expressing TRAIL-R1WT displayed
substantially increased sensitivity to apoptosis or cell death
induced by TRAIL, 4C9 or TRAIL-functionalized nanoparticles
(NPT)25 (Figure 2c, Supplementary Figures S4a and b). In
contrast, cells expressing TRAIL-R1N156A displayed reduced
sensitivity to TRAIL agonists (Figure 2c, Supplementary
Figures S4a and b). Apoptosis induced by TRAIL-R1 was
not affected by benzylGalNac (Supplementary Figure S4c), a
general inhibitor of O-glyc, while this treatment does restrict
TRAIL-R2 signaling.9 Confirming that benzylGalNac selec-
tively inhibited O-glyc and had no effect on N-glyc, benzyl-
GalNac treatment led to loss of α2,3-linked sialylation on
O-glyc proteins, but not on N-glyc proteins, using Maackia
amurensis lectin II and Sambucus nigra lectin, respectively
(Supplementary Figure S4d).
TRAIL bound to recombinant TRAIL-R1WT-Fc, TRAIL-
R1N156A-Fc and TRAIL-R2WT-Fc with similar affinities (8, 8.7
and 5.3 nM, respectively, measured by biolayer interferome-
try) (Figure 2d and Supplementary Figure S5a). TRAIL-R1-Fc-
binding affinities to 293 T cells expressing membrane-bound
TRAIL were also similar (Supplementary Figure S5b), indicat-
ing that impaired ligand binding is an unlikely cause for the
decreased pro-apoptotic activity of TRAIL-R1N156A. Instead,
loss of function in U2OS cells expressing TRAIL-R1N156A was
associated with reduced caspase-8 and -10 recruitment within
the TRAIL DISC (not shown) and restricted receptor cluster-
ing, as evidenced by immunofluorescence (Figure 2e).
Contribution of N-glycosylation to TRAIL-R1-induced apop-
tosis was further investigated in HCT116 and MDA-MB-231
cells double deficient for TRAIL-R1 and TRAIL-R2 (DKO)26
that were reconstituted with WT, N156A or N156Q forms of
TRAIL-R1. Surface expression levels of the WT and mutated
receptors were comparable for all constructs (Figure 3a) and
as expected mutations N156A and N156Q prevented N-gly-
cosylation (Figure 3b). TRAIL-induced cell death was almost
fully restored with WT TRAIL-R1 but not with TRAIL-R1N-glyc
mutants (Figure 3c). Consistently, aggregation of TRAIL-R1
and recruitment of caspase-8 and -10 within the TRAIL DISC
were decreased in cells expressingN-glyc-deficient TRAIL-R1
(Figures 3d–f). Taken together, these results indicate that
N-glyc of TRAIL-R1, although not required for ligand binding,
stimulates TRAIL-induced apoptosis through enhanced
receptor clustering and DISC formation.
N-glycosylation of TRAIL-R is evolutionarily conserved.
Since mTRAIL-R encodes three potential N-glyc sites in its
two CRDs, we determined whether these sites were
modified. mTRAIL-R isolated in extracts of L929 fibrosar-
coma or B16 melanoma cells migrated at a MW of 55-60 kDa,
higher than predicted from its amino acid sequence (42 kDa)
(Figure 4a). Treatment of these cells with the N-glycosylation
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inhibitor tunicamycin or digestion of L929 cell extracts with
PNGase F, converted mTRAIL-R to the expected 42 kDa
band, demonstrating that these predicted sites are indeed
modified by N-glyc (Figures 4a and b).
Mouse tumor cell lines are less sensitive to TRAIL-
mediated apoptosis than human ones. Unlike most
human tumor cell lines in which cell death can be induced
by recombinant His-hTRAIL or by crosslinked Flag-TRAIL,
we found that several mouse tumor cell lines were quite
resistant to soluble human and mouse TRAIL (Supple-
mentary Figure S6a), despite expressing moderate (B16) to
high (L929, EMT6H) levels of mTRAIL-R at both the mRNA
and cell-surface protein levels (Supplementary Figures S6b
and c). Enforced receptor aggregation induced by cross-
linking of a soluble Flag-tagged mTRAIL, however, enhanced
apoptosis of L929 cells, but had no effect on B16 cells
(Figure 4c and Supplementary Figure S6d). The agonistic
anti-mTRAIL-R antibody (clone MD5-1) failed to induce
apoptosis when used in solution (Supplementary
Figure S6e), but as reported,27 could induce apoptosis of
both L929 and EMT6H cells when adsorbed to cell culture
dishes (Figure 4d). B16 cells, however, remained resistant
even to plate-coated MD5-1 or crosslinked soluble Flag-
mTRAIL (Figure 4d and Supplementary Figure S6d).
Although B16 cells expressed detectable mTRAIL-R at the
cell surface, its levels were lower than those of L929 and
EMT6H cells (Supplementary Figure S6c). Consequently, we
tested whether ectopic expression of mTRAIL-R in B16 or
L929 cells could enhance their sensitivity to crosslinked Flag-
mTRAIL, and found it did for both these cell lines (Figure 4e
and Supplementary Figure S6f). In addition, an oligomerized
version of mTRAIL (coined Superkiller) also induced more
apoptosis of cells engineered to express higher levels of
mTRAIL-R, an effect that was further enhanced after treat-
ment with the protein synthesis inhibitor cycloheximide
(Supplementary Figure S6g). Nevertheless, increased
mTRAIL-R expression was still unable to confer sensitivity of
these two tumor cell lines to non-crosslinked TRAIL (Figure 4e
and Supplementary Figure S6f). However, expression of a
chimeric receptor composed of the extracellular domain of
human TRAIL-R2 fused to the intracellular domain of mTRAIL-
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Figure 1 TRAIL-R1 is N-glycosylated in human cancer cell lines. (a) Sequence comparison of the extracellular domain of TRAIL-R1 (TNFRSF10A), TRAIL-R2 (TNFRSF10B)
and mouse TRAIL-R. O-glycosylated threonine and serine sites demonstrated to regulate TRAIL-R2-induced apoptosis are shown in orange boxes.9 Serine or threonine sites
predicted to be O-glycosylated (GlycoEP server) are shown in red. Predicted N-glycosylation sites (NetNGlyc1.0 and GlycoEP servers) are depicted in green boxes. Conserved
cysteines are highlighted in pale gray boxes. (b) Flow cytometric analysis of TRAIL-R1 and TRAIL-R2 expression in two human colorectal cancer cell lines, SW480 and HCT116.
Gray-filled histogram, isotype control. White-filled histograms, TRAIL-R1 or TRAIL-R2 staining. (c) Cell viability of SW480 (white circles) and HCT116 (black squares) obtained by
methylene blue staining, after stimulation with increasing concentrations of His-hTRAIL, 4C9 (TRAIL-R1 selective ligand) or M1d (TRAIL-R2 selective peptidomimetic) as
indicated. Data are the mean±S.D. (n= 3). (d) Cell viability of B-cell lymphomas, VAL (white circles), BL2 (white squares), RL (gray squares), SUDHL4 (black squares) and
Ramos (black circles) measured by alamar blue staining after exposure of increasing concentrations of His-hTRAIL, 4C9, M1d or Fas ligand. Data are the mean± S.D. (n= 3).
(e) TRAIL-R1 and TRAIL-R2 immunoblots obtained from SW480 and HCT116 cell lysates after PNGase F treatment. GAPDH was used as a loading control. (f) TRAIL-R1
immunoblot obtained from indicated B-cell lymphoma cell lysates after PNGase F treatment. HSC70, loading control. One representative blot is shown. The black arrow
corresponds to WT TRAIL-R1. Gray arrow shows non-glycosylated TRAIL-R1
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R was able to induce apoptosis in the absence of TRAIL
crosslinking (Figure 4f), suggesting that the inability of soluble
TRAIL to induce mTRAIL-R apoptosis in several cell lines
upon binding to soluble TRAIL is due to an inability of the
receptor ectodomain to mediate higher-order aggregation in
the absence of forced crosslinking, and not due to an inherent
difference in downstream signaling.
Cell death induced by mouse TRAIL receptor is regulated
by N-glycosylation. In order to determine the impact of
mTRAIL-R N-glycosylation on TRAIL-induced apoptosis,
mTRAIL-R mutants lacking one, two or all three N-glycosyla-
tion sites (N99, N122 and/or N150) were generated and
expressed in B16 cells. Immunoblot analysis demonstrated
that all three asparagines are N-glycosylated in B16 cells
(Figure 5a). With the exception of the triple mutant, whose
surface expression at the cell surface was reduced by
twofold, all single and double mutants were expressed
similarly to WT mTRAIL-R in B16 cells (Figure 5b and
Supplementary Figure S7a). mTRAIL-R-induced apoptosis
(using crosslinked Flag-mTRAIL, 'Superkiller' His-mTRAIL or
plate-bound MD5-1) was reduced in mutants N99/122A and
N99/122/150A, while other mutants behaved like WT
(Figures 5c, d and Supplementary Figure S7b). Mutations
N99/122A and N99/122/150A had essentially no impact on
ligand binding (Supplementary Figure S7c), but impaired
receptor clustering upon ligand binding in both B16 and
U2OS cells (Supplementary Figure S7d). In addition,
mTRAIL-RN99/122A also showed enhanced internalization
compared with WT (Supplementary Figure S8). These results
indicate that N-glyc of mTRAIL-R favors TRAIL-induced
apoptosis of tumor cells.
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Figure 2 Mutation of the unique TRAIL-R1 N-glycosylation site inhibits TRAIL-induced cell death. (a) Flow cytometric analysis of TRAIL-R1 and TRAIL-R2 in mock-, TRAIL-
R1 WT- or TRAIL-R1 N156A-infected U2OS cells. (b) TRAIL-R1 immunoblot obtained from cell extracts treated or not with PNGase F of TRAIL-R1-WT or TRAIL-R1-N156A-
infected U2OS cells. HSC70 was used as a loading control. (c) Quantification of apoptosis in U2OS cells expressing or not WTor N156A TRAIL-R1 cells stimulated for 16 h with
1 μg/ml His-hTRAIL or 4C9. Data are the mean± S.D. (n= 3), *Po0.05; **Po0.01; NS= not significant. (d) Anti-human IgG Fc capture biosensors were functionalized with
TRAIL-R1-Fc WT or TRAIL-R1-Fc N156A recombinant soluble receptors. Binding/dissociation kinetics of indicated Flag-hTRAIL concentrations were monitored by BioLayer
Interferometry (BLI) using an Octet Red instrument. Binding constants KD (M), kon (M
− 1s− 1) and koff (s
− 1) of sensograms are shown below. (e) TRAIL DISC composition in
WTor N-glycosylation-deficient TRAIL-R1 (N156A)-expressing U2OS cells was analyzed by immunoblot after His-hTRAIL stimulation (1 μg/ml) and immunoprecipitation using
either an anti-histidine or an anti-caspase-8 antibody. The black arrow corresponds to fully glycosylated TRAIL-R1. Gray arrow shows non-glycosylated TRAIL-R1. (f) TRAIL
immunofluorescence staining of U2OS cells expressing WTor N156A TRAIL-R1 or not (Mock) stimulated with Flag-hTRAIL crosslinked with M2 for the indicated time at 37 °C,
fixed and stained using an anti-M2 antibody. Unstimulated cells were fixed and incubated in the presence of crosslinked TRAIL for 30 min on ice. Cell nuclei were counterstained
with DAPI
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The HCMV UL141 glycoprotein alters TRAIL-R1
N-glycosylation. Recently we showed that the HCMV
UL141 glycoprotein binds to TRAIL-R1 and TRAIL-R2,
restricting their cell-surface expression and desensitizing
infected cells to NK cell-mediated killing.15 In agreement with
these findings, cell-surface levels of both death receptors was
reduced in primary human dermal fibroblasts (neonatal
human dermal fibroblasts, NHDF) upon infection with
HCMVWT, but not with a mutant virus lacking an intact
UL141 open reading frame (HCMVΔUL141) (Figure 6a). As a
control, cell-surface expression of MHC-I was shown to be
reduced in NHDF infected with both WTand ΔUL141 viruses
(Figure 6a). Reduced TRAIL-R1 and TRAIL-R2 surface
expression was not due to UL141-mediated inhibition of
gene expression or translation, as the total protein levels of
both death receptors was in fact markedly increased in cells
infected with either HCMVWT or HCMVΔUL141 (Figure 6b and
Supplementary Figure S9a). In addition, the size of TRAIL-R1
was slightly reduced upon infection with HCMVWT but not with
HCMVΔUL141. A treatment with PNGaseF revealed that this
was due to a reduction in the size/composition of N-glyc
(Figure 6b and Supplementary Figure S9). Although the
N-linked glycan of TRAIL-R1 was sialylated (neuraminidase
treatment modestly reduced the MW of TRAIL-R1), desialyla-
tion alone did not explain the reduced MW of TRAIL-R1 in
HCMVWT-infected cells, as size differences still persisted
after neuraminidase treatment (Supplementary Figure S9b).
Similar results were obtained upon infection with the mouse
virus: an infection with MCMVWT reduced the MW of
mTRAIL-R more efficiently than an infection with a virus
lacking m166 (MCMVΔm166), the functional ortholog of
UL14116 (Supplementary Figures S9c and d). The decreased
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Figure 3 Glycosylation of TRAIL-R1 is required for TRAIL DISC formation. (a) Flow cytometric analysis of TRAIL-R1 and TRAIL-R2 in parental, TRAIL-R1 and TRAIL-R2
double deficient (DKO), DKO reconstituted with TRAIL-R1 WT (DR4recWT), TRAIL-R1 N156A (DR4recN156A) or TRAIL-R1 N156Q (DR4recN156Q), HCT116 or MDA-MB-231
cells. (b) Western blot of TRAIL-R1 and (c) apoptosis analysis in corresponding cells. Data are the mean± S.D. (n= 3), *Po0.05; ***Po0.001; NS= not significant. (d) TRAIL
DISC composition in WTor N-glycosylation-deficient TRAIL-R1 expressing HCT116 and MDA-MB-231 cells was analyzed by immunoblot after His-hTRAIL stimulation (1 μg/ml)
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DR4recN156A HCT116 cells, after stimulation as above. (f) Immunofluorescence analysis of TRAIL-R1 aggregation after 30 min stimulation with 1 μg/ml His-hTRAIL using an
anti-TRAIL-R1 antibody. Cell nuclei were counterstained with DAPI
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MW of mTRAIL-R was not solely due to differences in
sialylation, because the difference persisted after treatment
with neuraminidase and sialidase A (Supplementary Figures
S9c and d). Thus, our results show that both human and
mouse CMV alter N-glyc of TRAIL-R1 and mTRAIL-R via the
UL141 and m166 proteins, respectively. Intesrestingly, N-glyc
of TRAIL-R1 appears detrimental for binding to UL141.
Indeed, 293 T cells transfected with a GPI-anchored version
of UL141, bound TRAIL-R1N156A-Fc significantly better than
TRAIL-R1WT-Fc, reaching an affinity comparable to that of
TRAIL-R2-Fc, which lacks N-glyc (Figure 6c).
Discussion
Until recently, proximal regulation of TRAIL signaling was
thought to occur primarily through homotypic protein–protein
interactions,7,28 but recent results have shown that
glycosylation of human TRAIL receptors can also plays a
role. Indeed, O-glycosylation of TRAIL-R2 is a prerequisite for
TRAIL/TRAIL-R2-mediated apoptosis and correlates directly
with the cellular expression levels of glucosyltransferases or
fucosyltranferases. O-glycosylation is required for receptor
clustering, DISC formation, caspase-8 recruitment and down-
stream signaling.9 However, despite this strong evidence
showing that O-glyc can regulate TRAIL-mediated apoptosis
through TRAIL-R2, which contains no N-glyc sites, nothing
was known with regard to the role that glycosylation might
play in regulating TRAIL-R1 signaling. TRAIL-R1 encodes
significantly fewer consensus O-glyc sites but harbors an
N-glycosylation site on N156 that is located within the
first CRD.
Here we provide experimental evidence that the TRAIL
apoptotic signaling pathway is regulated by N-glycosylation.
We demonstrate that both human TRAIL-R1 and mouse
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TRAIL receptor are N-glycosylated and that this post-
translational modification enhances their ability to trigger
apoptosis. Unlike TRAIL-R2,9 however, apoptosis induced by
TRAIL-R1 was not affected by the general inhibitor of O-glyc
benzylGalNac (Supplementary Figure S4b). As opposed to
Fas,21 the N-glyc sites of TRAIL-R1 orthologs are located
within the '50's loop', a major TRAIL interaction site. However,
our studies show that N-glyc at this location does not affect
TRAIL-binding or its steady-state cell-surface expression,
excluding these as possibilities for restricted signaling.
Instead, our findings support a model where N-glyc alters
the distribution of TRAIL-R1 and/or its arrangement at the cell
surface before ligand binding, and also regulates receptor
clustering/aggregation upon TRAIL stimulation, as this was
reduced in cells expressing the N-glyc mutants of both TRAIL-
R1 or mTRAIL-R after TRAIL stimulation. These findings
suggest that this post-translational modification is an evolu-
tionarily conserved mechanism to modulate TRAIL receptor
signaling, perhaps by enhancing homotypic receptor interac-
tions, or potentially regulating associations with yet to be
identified cellular partners.
In agreement with a model where N-glyc might regulate
heterotypic protein interactions of TRAIL-R1, the HCMV
UL141 glycoprotein exhibited ~ 5 fold higher binding affinity
for the non-glycosylated form of TRAIL-R1. This finding is
noteworthy, as UL141 potently restricts host innate antiviral
defenses by blocking the cell-surface expression of both
human TRAIL death receptors.15 UL141 displays lower affinity
for N-glyc TRAIL-R1 than O-glyc TRAIL-R2, suggesting that
binding of non/under N-glyc TRAIL-R1 by UL141 may be
favored in infected cells. This would be consistent with a large
proportion of UL141 being localized to the endoplasmic
reticulum and endosomal compartment(s) in HCMV-infected
cells.15 In this regard, irrespective of whether UL141 has
evolved thisN-glyc sensitivity in order to bind TRAIL-R1 during
its initial synthesis/translation, or to ‘trap’ it at the cell surface or
during its recycling, this strategy is likely to provide the virus
with an advantage to attenuate innate immune defences
involving TRAIL.
Understanding more precisely how O- and N-glycosylation
regulate TRAIL receptor trafficking, DISC formation and
apoptosis is likely to be important not only to comprehend
TRAIL's selective antitumoral properties but also may be key
to design novel rational TRAIL-derivative compounds for use
in cancer therapy.29 The fact that TRAIL-R1 is N-glycosylated
while TRAIL-R2 isO-glycosylated could also provide potential
clues to the differential promotion of apoptosis by these two
receptors in some tumor cell types.30 However, this
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preferential engagement is unlikely to be regulated primarily
by a loss of TRAIL-R1N-glyc, as it is fully glycosylated in all the
tumor cell lines we have examined, including those inducing
cell death primarily through TRAIL-R1 signaling.O- andN-glyc
proteins can undergo additional post-translational modifica-
tions, including sialylation, fucosylation or terminal glycan
branching.31,32 As recently reported for EGFR33 and Fas,34
these terminal modifications have the potential to affect TRAIL
receptor pro-apoptotic signaling. Accordingly, a deficiency in
GPD-mannose-4-6-dehydratase, a GDP-mannose converting
enzyme essential for de novo fucosylation, was found to inhibit
TRAIL- and Fas-ligand-induced cell death.35 Moreover, a
galactose-binding lectin, galectin-3, has been reported to both
inhibit and enhance TRAIL-mediated apoptosis.36–38 It will be
interesting in the future to test whether this might be related to
TRAIL receptor glycosylation status.
Keeping in mind that neoplastic transformation involves
drastic changes in glycosylation,39 galectin-3 expression40
and N-terminal sugar modifications,41 all should be
considered as potentially important regulators of the
TRAIL-mediated tumor killing.
Altogether, our results provide the first evidence that
TRAIL-R1 N-glycosylation likely plays an important role in
modulating both TRAIL-mediated antiviral responses and
tumor immune surveillance.
Material and Methods
Cell lines and viruses. The mouse mammary cell line clone EMT6H, which
derives from the breast epithelial EMT-6 cells,1 was kindly given by Professor Ali
Bettaied (Dijon, France), the human osteosarcoma U2OS cell line was obtained
from Professor Serge Lebecque (Lyon, France), the human B Lymphoma cell lines,
VAL, RL, SUDHL4 and BL2 were provided by Dr. Thierry Guillaudeux (Rennes,
France), the Ramos human B Lymphoma cell line was provided by Dr. Jean-Ehrland
Ricci (Nice, France) and the MDA-MB-231 breast carcinoma cell line was obtained
from Dr. Patrick Legembre (Rennes, France). HCT116 colon carcinoma cells were
from the ATCC (LGC Standards, Molsheim, France). TRAIL-receptor-deficient
HCT116 and MDA-MB-231 (DKO) cells were generated using the TALEN approach
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as described by Dufour et al.26 Primary MEF were generated from WTand mTRAIL-
R− /− (a kind gift from Dr Astar Winoto3) d13.5 embryos of C57BL/6 mice. NHDF cells
were obtained from Clonetics (San Diego, CA, USA). All other cell lines were
purchased from the American type culture collection (ATCC). Mouse B16, L929 cell
lines and human B-lymphomas were maintained in RPMI medium (Lonza, Levallois-
Perret, France) and primary MEF and NIH-3T3 cells were maintained in DMEM
(Gibco, Thermo Fisher Scientific, Courtaboeuf, France). EMT6H cells were cultured in
EMEM medium (Lonza). Human colon carcinoma cells HCT116 and SW480, U2OS
and NHDF cells were cultured in DMEM medium (Lonza). For NHDF, insulin and
bFGF (Sigma-Aldrich, Lyon, France) were added to the media. All cells were cultured
with 10% fetal calf serum (Lonza) in 5% CO2. HCMV (Merlin strain) WTand ΔUL141
viruses 4 were generated in NHDF cells and purified by pelleting cell-associated plus
cell-free virus through a 20% sorbitol cushion, as described.5 MCMV (K181 BAC-
derived strain) WT and Δm166 (containing 2 stop codons inserted after the 44th
amino acid by ‘traceless mutagenesis’ of the m166 orf 6) virus stocks were produced
in primary MEF as described.6 Cells were infected at an MOI= 2 for all experiments.
Real-time PCR assay. RNA was extracted using the RNeasy Mini Kit from
Qiagen (Les Ulis, France). M-MLV Reverse Transcriptase (Promega, Charbonnières,
France) was used to synthesize cDNAs from total RNA. Real-time PCR was
performed in triplicate using the syber green PCR master Mix from Applied
Biosystems (Courtaboeuf, France) and analyzed using the 7500 Fast Detection
System (Applied Biosystems). Specific forward and reverse primers were: murine
TRAIL-R, 5′-CCT CTC GGA AAG GGC ATT C-3′ and 5′-TCC TGCTCGATG AC
C AGC T-3′7 and murine cyclophilin A, used as a standardizing control, 5′-GGC
CGA TGA CGA GCC C-3′ and 5′-TGT CTT TGG AAC TTT GTC TGC AA-3′.
Ligand production, chemicals and antibodies. Flag-tagged recombi-
nant soluble murine TRAIL, his-tagged human TRAIL and Fas ligand were produced
and used as described previously.8 Mouse SuperKiller His-TRAIL (SuperKiller His-
mTRAIL) was purchased from Adipogen (Coger, Paris, France). TRAIL-R1 selective
TRAIL ligand (4C9) and TRAIL-R2 selective peptidomimetic (M1d) were produced
as described earlier.9,10 Functionalized nanoparticules with TRAIL (NPT) are
described elsewere.11 MD5-1 antibody was purchased from eBioscience (Paris,
France) and the anti-Flag M2 monoclonal antibody was from Sigma-Aldrich.
Crosslinking of TRAIL was achieved by incubating the ligand with anti-Flag M2
antibody for 30 min at 4 °C with mixing prior to cell treatment. For western blot
analysis of human proteins, anti-TRAIL-R2 antibody was purchased from Chemicon
(Millipore, Molsheim, France), anti-FADD from Transduction Laboratories (BD
Biosciences, Le Pont de Claix, France), anti-caspase-8 and anti-caspase-10 were
from Medical & Biological Laboratories (Clinisciences, Montrouge, France). Murine
DR5 was revealed by western blot using the anti-mouse TRAIL-R2 antibody from
Leinco Technologies (St. Louis, MO, USA). Flow cytometry analysis for murine DR5
was performed using the MD5-1 antibody, with a PE-conjugated anti-armenian
hamster secondary antibody from BD Biosciences. For human receptors, anti-
TRAIL-R1 (wB-S26) and anti-TRAIL-R2 (B-D37) antibodies were provided by
Gen-Probe (Diaclone, Besançon, France). The secondary antibody was an Alexa-
488-coupled goat anti-mouse from Molecular Probes (Invitrogen, Cergy Pontoise,
France). Tunicamycin and swainsonine were from Sigma-Aldrich. PNGaseF was
purchased from New England Biolabs (Evry, France). Neuraminidase and sialidase
A were from Europa-Bioproducts (Cambridge, England). For apoptosis measure-
ment, Annexin V (556422) and 7AAD (559925) were from BD Biosciences.
Plasmid constructions. The parental murine full-length TRAIL-R and human
TRAIL-R1 or TRAIL-R2 retroviral pMSCV vectors were obtained by subcloning using
HindIII/XhoI from the pCR3-mTRAIL-R, pCR3-TRAIL-R1 and pCR3-hTRAIL-R2
vectors.12,13 Chimeric mouse/human TRAIL receptor constructs were generated as
follows. First, a modified version of the full-length hTRAIL-R2 harboring two restriction
sites, BglII and BamHI, encompassing the transmembrane domain was obtained by
synthesis from Genscript (Piscataway, NJ, USA) and subcloned into the pMSCV
retroviral vector using HindIII/XhoI to generate pMSCV-hTRAIL-R2-BglII-TM-BamHI.
Next, mTRAIL-R extracellular and intracellular domains, ECD and ICD, respectively,
were obtained by PCR from pCR3-mTRAIL-R using the following primer sets:
mTRAIL-R (ECD) 5′-aaa aga tct AAC CTA GGC CTC TGG ATA GGA G-3′ and
5′-ttt tgg gcc cTC AAA CGC ACT GAG ATC CT-3′; mTRAIL-R (ICD) 5′-aaaaAA
GCT TAT GGA GCC TCC AGG ACC CAG-3′ and 5′-ttt tgg atc cAT GCC
AAG ATG CCC AAG CCG-3′. PCR products were digested using BglII/ApaI or HindIII/
BamHI, respectively, and digestion products were inserted into pMSCV-hTRAIL-R2-
BglII-TM-BamHI to generate pMSCV-mTRAIL-R(ECD)-hTRAIL-R2(ICD) and pMSCV-
hTRAIL-R2(ECD)-mTRAIL-R(ICD): referred to in the text as h/mTRAIL-R or m/
hTRAIL-R2. Human TRAIL-R1 N156A or N156Q and Mouse TRAIL receptor variants
N99A, N122A, N150A mutants were created by routine site-directed mutagenesis
from the pMSCV-mTRAIL-R vector using the following sets of primers: N156A
5′-ACA CCG CCG CTT CCA ACA ATT TGT TTG CTT GCC-3′ and 5′-TGG AAG
CGG CGG TGT AAC CCA CAC CCT CTG T; N156Q, 5′-ACA CCC AAG
CTT CCA ACA ATT TGT TTG CTT GCC-3′ and 5′-TGG AAG CTT GGG TGT
AAC CCA CAC CCT CTG T; N99A, 5′-CTA CAC CAG CCA TTC CGC CCA
TTC TCT GGA TTC-3′ and 5′-GAA TCC AGA GAA TGG GCG GAA TGG
CTG GTG TAG-3′; N122A, 5′-CGT AGA AAC CCG ATG CGC CAT AAC CAC AAA
TAC G-3′ and 5′-CGT ATT TGT GGT TAT GGC GCA TCG GGT TTC TAC G-3′;
N150A, 5′-CTG CCA GTC ATG CTC TGC ATG CAC TGA CGG GGA AG-3′ and
5′-CTT CCC CGT CAG TGC ATG CAG AGC ATG ACT GGC AG-3′ to generate
pMSCV-hTRAIL-R1-N156A, pMSCV-hTRAIL-R1-N156Q, pMSCV-mTRAIL-R-N99A;
pMSCV-mTRAIL-R-N122A and pMSCV-mTRAIL-R-N150A. Double and triple mutants
were obtained as above through successive site-directed mutagenesis to generate
pMSCV-mTRAIL-R-N99/122A; pMSCV-mTRAIL-R-N122/150A, pMSCV-mTRAIL-R-
N99/150A and pMSCV-mTRAIL-R-N99/122/150A. The UL141-GFP fusion plasmid
was generated as described,5 and the UL141-GPI expression plasmid was generated
by PCR amplification of the UL141 ectodomain (FIX strain5) and cloning upstream of
the sequence encoding for the addition of the TRAIL-R3 GPI linkage.14 Sequences of
all constructs were confirmed by sequencing.
Glycosidase treatments. Cell lysates were prepared using a NP40 lysis
buffer containing 1% NP40, 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
and a proteinase inhibitor cocktail (Roche, Meylan, France). Ten micrograms of
protein were digested with PNGase F or sialidases (neuraminidase or sialidase A)
according to the manufacturer’s recommendations (Europa-Bioproducts, Cam-
bridge, England). Alternatively cells were incubated in the presence of 1 μg/ml
tunycamycin before lysis.
Retrovirus production and cell transduction. The generation of
viruses has been described previously.15 Viral particles of the various human and
mouse TRAIL receptor constructs were produced to transduce mouse B16F10,
L929, EMT6H tumor cell lines as well as the human tumor cell line SW480.
Transduction was performed for 16 h in six-well plates on 0.1 to 0.3 × 106 cells in the
presence of Polybrene (8 μg/ml). Cells were then washed in phosphate-buffered
saline, harvested, plated in complete medium containing puromycin (2.5 μg/ml) and
incubated for 3 days before amplification and subsequent analysis of the polyclonal
populations.
Cell viability assays. TRAIL ligands (Flag-mTRAIL; His-hTRAIL or Super-
Killer His-mTRAIL) or MD5-1 were titrated in 96-well plates using 5 × 104 cells per
well, incubated at 37 °C for 16 h. In another set of experiments, the crosslinking
anti-Flag M2 monoclonal antibody was titrated in the presence of 100 ng/ml Flag-
mTRAIL as above. Alternatively, the M2 antibody was used at 1 μg/ml to titrate Flag-
mTRAIL. In other experiments, the agonist anti-mTRAIL-R antibody MD5-1 was
incubated in protein A-coated plates (Fisher Scientific, Illkirch, France) in PBS
overnight at 4 °C with gentle rocking at increasing concentrations. The next day,
unbound antibodies were removed and plates were washed three times in sterile
PBS before adding 4 × 104 cells per well in complete medium. Plates were then
incubated at 37 °C for 16 h with 5% CO2. Cell viability was either measured by
methylene blue (adherent cells) or Alamar blue staining (Fischer Scientific).
Apoptosis measurement. Apoptosis was determined by detection of
phosphatidylserine externalization after co-labeling with Annexin V-FITC/propidium
iodide, according to the manufacturer's instructions. Analyses were performed on a
FACScan cytometer (BD Bioscience). Apoptosis is displayed as the percentage of
cells presenting a positive staining compared with nontreated cells as control. Each
experiment was carried out independently at least three times.
Immunoprecipitations. For TRAIL DISC analysis in human cells expressing
the murine TRAIL receptor, 8 × 107 cells in PBS were stimulated in 1 ml of complete
medium with 5 μg Flag-TRAIL with or without 10 μg M2 antibody for 60 min at
37 °C. Cells were then washed with PBS before lysis in NP40 lysis buffer containing
a protease inhibitor cocktail. Cell lysates were pre-cleared with Sepharose 6B
(Sigma-Aldrich) for 1 h, then the DISC was immunoprecipitated overnight with
protein G-coated beads (Amersham Biosciences, Les Ullis, France) at 4 °C in the
presence of an anti-caspase-8 antibody (C20, SC6136). Beads were washed four
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times with NP40 lysis buffer, and then immunoprecipitated complexes were eluted in
loading buffer (63 mM Tris-HCl pH 6.8, 2% SDS, 0.03% phenol red, 10% glycerol,
100 mM DTT), then boiled for 5 min before analysis by western blot.
Western blotting. Immunoprecipitates or cell lysates were separated by
SDS-PAGE and then transferred to PVDF membrane. Nonspecific binding sites
were blocked by incubation in PBS containing 0.5% Tween 20 and 5% powdered
milk. Immunoblots were incubated with a specific primary antibody and then an
HRP-conjugated secondary antibody. Blots were developed using an enhanced
chemiluminescence method according to the manufacturer's protocol (Amersham).
Binding studies. Binding data processing was performed with FortéBio Data
Analysis Software version 7.1.0.36 with Savitsky-Golay filtering to reduce noise.
Association and dissociation data were fit globally (single phase exponential decay
function) in Prism version 5.0a software (GraphPad Software, San Diego, CA, USA).
In silico analysis. Sequence alignment across species was performed using
CLC Sequence Viewer 6.5.2 software (CLC bio, Aarhus, Denmarkoctet). O- and
N-glycosylated sites were predicted using the GlycoEP server (prediction of
glycosides in eukaryotic glycoproteins),16 NetNGlyc1.0 and NetOGlyc 3.1 servers
available at http://www.imtech.res.in/raghava/glycoep/ and at the CBS (Center for
biological sequence analysis (http://www.cbs.dtu.dk/services/NetNGlyc/ or NetO-
Glyc/), respectivley. Representation of TRAIL-R1 and mTRAIL-R 3D structure
prediction were inferred from TRAIL-R2 crystallographic structure using PHYRE2
Protein Fold Recognition server,17 at http://www.sbg.bio.ic.ac.uk/phyre2. Evolu-
tionary history of primate and rodent TRAIL agonist receptors was inferred using the
Neighbor-Joining method using the software MEGA 6.06 (Molecular Evolutionary
Genetics Analysis).
Statistical analysis. Statistical analysis was performed using the Student's
t-test. All statistical analyses were performed using Prism version 5.0a software
(GraphPad Software, San Diego, CA, USA). *Po0.05 and **Po0.01 were
considered significant.
Production of soluble TRAIL receptors and BLI biolayer inter-
ferometry analysis. Murine mTRAIL-R variants N99A, N122A, N150A
mutants and human TRAIL-R1 variant fused to human Fc IgG1 were created by
routine site-directed mutagenesis from pCR3-TRAIL-R1-hFc or pCR3-mTRAIL-R-
hFc vectors using the following sets of primers: TRAIL-R1 forward 5′-
GGG TGT GGG TTA CAC CGC CGC TTC CAA CAA TTT G-3′, reverse 5′-
CAA ATT GTT GGA AGC GGC GGT GTA ACC CAC ACC C-3′ and primer sets for
mTRAIL-R described in Plasmid constructions. All constructs were confirmed by
sequencing. To produce these soluble recombinants receptors, 6 × 106 293 T cells
were seeded in 10 cm tissue culture dish and cultured in DMEM medium (Lonza)
with 10% fetal calf serum for 24 h. 293 T cells were then transfected with pCR3-
mTRAIL-R-WT-hFc, pCR3-mTRAIL-R-N99/122A-hFc, pCR3-mTRAIL-R-N99/122/
150A-Fc, pCR3-TRAIL-R1-WT-hFc, pCR3-TRAIL-R1-N156A-WT-hFc using calcium
phosphate transfection method. After 16 h, cells were washed twice with HBSS,
then 10 ml of Opti-MEM (Invitrogen) were added in each 10 cm tissue culture dish.
Seventy-two hours latter, cell culture supernatant was collected, cleared by
centrifugation and filtered. Production of soluble hFc-fused WTor mutant mTRAIL-R
or TRAIL-R1 was assessed by western blot using the anti-mouse TRAIL-R2
antibody from Leinco Technologies and the anti-TRAIL-R1antibody (wB-K32) from
Gen-Probe (Diaclone, Besançon, France). Purification of hFc fusion proteins was
achieved by an overnight pull-down with protein A/G-coated beads (Millipore) at
4 °C with mixing. Beads were washed four times with PBS, and pulled-down
proteins was eluted in 100 mM glycine-HCl, pH 2. pH neutralization was achieved
by adding 1M Tris, pH 9.0. Quantitation of hFc fusion proteins were determined
using an Octet Red System with anti-human IgG quantitation (AHQ) biosensors
(FortéBIO). All Octet experiments were designed and analyzed with data acquisition
software (7.1) and data analysis software (7.1), respectively. Data were fit with
GraphPad version 5.
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